This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In June this year, it was announced that the US Food and Drug Administration (FDA) had granted UK-based OxfordVR a breakthrough device designation for its gameChangeVR treatment to deliver immersive cognitive behaviour therapy (CBT) to people suffering from schizophrenia and other mental illnesses. million people in the UK and 2.7
Non-pharmacological interventions like CBT are generally recommended as first-line treatment for fibromyalgia, a complex disorder with no known cause, but these are usually delivered by a therapist – often in short supply in health systems around the world. It is available on prescription from healthcareproviders.
Whether you are marketing a new medical product or creating animations for instructional reasons, you must satisfy regulatory criteria established by the FDA, EMA, or another health authority. Regulatory compliance is obviously very important, hence every animation we create satisfies industry standards including FDA and EMA criteria.
During my pharmacology class, I learned that there are no safe drugs, only safe patients. It also underscores the need for patients to communicate openly with their healthcareproviders about any health concerns or issues they may have. This includes potential side effects or adverse reactions to medications.
While for other patients the possible adverse side effects from medication may prevent them from finding pharmacological therapies effective. Throughout 2016 and until mid-2019 we conducted a deep technology due diligence, as well as market research, and met and spoke with dozens of mental healthcareproviders.
Unsurprisingly, the US FDA has reported a noticeable increase in the number of submissions that use AI/machine learning (ML) components in recent years; in 2021, they received more than 100 submissions wherein AI use was reported.
Did you know that a well-trained pharmaceutical sales rep can be the driving force behind a healthcareprovider's decision-making process? Training focused heavily on face-to-face interactions, with an emphasis on building relationships with healthcareproviders. That’s right. But it wasn't just about being personable.
In 2017, the US Food and Drug Administration (FDA) broke ground by approving the first drug with an embedded biosensor to track its use. Yet, despite the landmark FDA approval, digital pills have not exploded in pharma. It potentially helps individuals lend some kind of concrete evidence to discussions with their healthcareprovider.
They must be familiar with the different national authorities; the Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other regulations that govern the pharmaceutical marketing and sales. This knowledge can include pharmacology, therapeutic areas, and data from clinical trials with different medications.
The Attorney General of Alabama has threatened to use an obscure law passed in 2006 to prosecute women who terminate a pregnancy using pharmacological means, shortly after the FDA made access to the drugs easier.
Dr Sean Cahill, PhD, the associate editor of the global, peer-reviewed journal LGBT Health, says “for most young people, healthcareprovided doesn’t even go beyond that [social affirmation of gender identity], but a lot of people… are misrepresenting what gender affirming care looks like in this country”.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content